RetinalGenix Technologies Inc. Stock

Equities

RTGN

US76133Y1055

Biotechnology & Medical Research

Delayed OTC Markets 12:47:02 2024-02-22 pm EST 5-day change 1st Jan Change
3.5 USD +12.90% Intraday chart for RetinalGenix Technologies Inc. -.--% +13.27%
Sales 2022 - Sales 2023 - Capitalization 54.35M
Net income 2022 -3M Net income 2023 -2M EV / Sales 2022 -
Net Debt 2022 0.16 Net Debt 2023 0.51 EV / Sales 2023 -
P/E ratio 2022
-35.8 x
P/E ratio 2023
-25.6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 31.1%
More Fundamentals * Assessed data
Dynamic Chart
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
RetinalGenix Technologies Inc. announced that it has received $4.65 million in funding CI
RetinalGenix Technologies Inc. announced that it expects to receive $4.65 million in funding CI
RetinalGeniX?? Technologies Inc. Contracts with Medsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration CI
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Medical Advisory Board CI
RetinalGeniX Technologies Inc. Appoints Dessislava Boneva to its Board of Directors CI
RetinalGenix Technologies Inc. Appoints Virender Ahluwalia as Interim Chief Financial Officer CI
RetinalGenix Technologies Inc. Appoints Stephen Tannenbaum to the Business Advisory Board CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
RetinalGeniX Technologies Inc. Announces the Submission of Two Provisional Patent Applications for Investigational Therapeutic Drugs CI
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device CI
RetinalGeniX Technologies Inc. Announces Institutional Review Board Approves to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration CI
RetinalGenix Technologies Inc. Appoints Fred Chasalow to the Medical Advisory Board of DNA-GPS CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day+12.90%
3 months+12.90%
6 months-22.05%
Current year+13.27%
More quotes
Current year
3.10
Extreme 3.1
3.50
1 year
3.00
Extreme 3
4.49
3 years
3.00
Extreme 3
20.00
5 years
3.00
Extreme 3
20.00
10 years
3.00
Extreme 3
20.00
More quotes
Managers TitleAgeSince
Founder - -
Chief Executive Officer 71 18-07-31
Director of Finance/CFO 66 Nov. 29
Members of the board TitleAgeSince
Chief Executive Officer 71 18-07-31
Director/Board Member 95 19-03-31
Director/Board Member - 22-07-25
More insiders
RetinalGenix Technologies Inc. is an ophthalmic research and development company. The Company is focused on developing technologies to screen, monitor, diagnose and treat ocular, optical, and sight-threatening disorders. The Company is engaged to treat vision loss and blindness due to diabetic retinopathy and maculopathy through two devices: Retinal Imaging Screening Device, a portable, retinal imaging system providing a 200-degree field of view without requiring pupil dilation; and RetinalCam, a home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7. RetinalCam, is anticipated to have the capability to be used by patients in a variety of locations, including at home, primary care centers, emergency rooms and telehealth centers and nursing homes. Its Retinal Imaging Screening Device technology enables high-risk individuals to send their physician digitized retinal images and stream video easily from their homes.
More about the company